Physician profile
Agustin Pimentel
NPI 1740498146
$6,870.41
in general payments reported to CMS, 2019-2025
14 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,192 · 2020: $1,812 · 2021: $592 · 2024: $99.00 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.96 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $3,953.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $1,800.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $492.50 | 2021 | |
| Amgen INC. | $153.21 | 2019 | |
| Intera Oncology, INC | $147.62 | 2025 | Intera |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2021 | |
| Pfizer INC. | $99.00 | 2024 | |
| Celgene Corporation | $39.80 | 2019-2020 | |
| Daiichi Sankyo INC. | $28.34 | 2025 | Datroway |
| Eusa Pharma (US) LLC | $24.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.54 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agustin Pimentel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.